Working... Menu

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises (SUSTAIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01895361
Recruitment Status : Completed
First Posted : July 10, 2013
Last Update Posted : October 2, 2017
National Heart, Lung, and Blood Institute (NHLBI)
Food and Drug Administration (FDA)
Information provided by (Responsible Party):
Reprixys Pharmaceutical Corporation

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2016
  Actual Study Completion Date : March 2016